Pharmaceutical - GlaxoSmithKline

Filter

Current filters:

GlaxoSmithKline

Popular Filters

76 to 100 of 415 results

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Cost is preventing boys receiving anti-cancer vaccine for HPV

Cost is preventing boys receiving anti-cancer vaccine for HPV

13-02-2014

While national health systems have been pushing to increase the human papillomavirus (HPV) vaccine uptake…

CervarixEuropeGardasilGlaxoSmithKlineHealthcareMerck & CoPharmaceuticalUSAVaccines

GlaxoSmithKline sales beat forecasts, as 4th-qtr net income nearly triples

GlaxoSmithKline sales beat forecasts, as 4th-qtr net income nearly triples

05-02-2014

UK pharma giant GlaxoSmithKline’s financial report for fourth-quarter and full-year 2013 pleased investors,…

FinancialGlaxoSmithKlinePharmaceutical

“Breakthrough Therapy” designation for GlaxoSmithKline’s Promacta/Revolade for SAA

“Breakthrough Therapy” designation for GlaxoSmithKline’s Promacta/Revolade for SAA

03-02-2014

The US Food and Drug Administration has granted “Breakthrough Therapy” designation for UK pharma…

GlaxoSmithKlinePharmaceuticalPromactaRare diseasesRegulationRevolade

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India

03-02-2014

Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…

Asia-PacificAstraZenecaFinancialGlaxoSmithKlineIndiaNovartisPfizerPharmaceuticalPricing

GSK’s Tafinlar and Mekinist combo shows improved survival in Phase III study

GSK’s Tafinlar and Mekinist combo shows improved survival in Phase III study

27-01-2014

UK pharma major GlaxoSmithKline announced that its Phase III study of the combination of Tafinlar (dabrafenib)…

GlaxoSmithKlineMekinistOncologyPharmaceuticalResearchTafinlarUK

Positive EMA/CHMP opinion for GlaxoSmithKline’s diabetes drug Eperzan

Positive EMA/CHMP opinion for GlaxoSmithKline’s diabetes drug Eperzan

24-01-2014

Among a batch of positive opinions issued today by the European Medicines Agency’ s Committee for Medicinal…

DiabetesEperzanGlaxoSmithKlinePharmaceuticalRegulation

Study shows Fostair has comparable efficacy to Seretide in asthma patients

Study shows Fostair has comparable efficacy to Seretide in asthma patients

20-01-2014

A study has shown that asthma patients may be switched from Seretide to Fostair at an equivalent or lower…

Chiesi FarmaceuticiFostairGlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonarySeretideUK

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

13-01-2014

Santaris Pharma, a Denmark-based clinical-stage biopharma company, has signed an agreement with UK drug…

GlaxoSmithKlineLicensingPharmaceuticalSantaris Pharma

GSK gains accelerated FDA approval for combination use of Mekinist and Tafinlar

GSK gains accelerated FDA approval for combination use of Mekinist and Tafinlar

09-01-2014

GlaxoSmithKline (LSE: GSK) says that the US Food and Drug Administration has approved Mekinist (trametinib)…

GlaxoSmithKlineMekinistOncologyPharmaceuticalRegulationTafinlarUKUSA

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

08-01-2014

UK pharma giant GlaxoSmithKline and US partner Theravance today announced the launch of Relvar Ellipta…

GlaxoSmithKlineMarkets & MarketingNorthern EuropePharmaceuticalRelvar ElliptaRespiratory and PulmonaryTheravanceUK

IQWiG says added benefit of GSK’s Tafinlar not proven

IQWiG says added benefit of GSK’s Tafinlar not proven

07-01-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlar

Blend Therapeutics names former GSK VP Richard Wooster as chief scientific officer

Blend Therapeutics names former GSK VP Richard Wooster as chief scientific officer

07-01-2014

US biopharmaceutical company Blend Therapeutics has appointed pharmaceutical industry veteran Richard…

Blend TherapeuticsBoardroomGlaxoSmithKlinePharmaceuticalUSA

Report: Health care companies lead the way in corporate compliance

27-12-2013

Health care companies are leading the way in terms of public trust and transparency, according to The…

AstraZenecaGlaxoSmithKlineLegalManagementPharmaceuticalReckitt BenckiserUK

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

22-12-2013

The US Food and Drug Administration has granted “Breakthrough Therapy” designation for tafenoquine,…

CervarixEuropeGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationtafenoquineTropical diseases

US FDA approves GSK/Theravance’s Anoro Ellipta for COPD

US FDA approves GSK/Theravance’s Anoro Ellipta for COPD

19-12-2013

The US Food and Drug Administration late yesterday approved Anoro Ellipta (umeclidinium and vilanterol…

Anoro ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravance

Merck & Co trialing MK-3475 with GSK’s pazopanib in renal cancer

Merck & Co trialing MK-3475 with GSK’s pazopanib in renal cancer

18-12-2013

US pharma giant Merck & Co says it has initiated a clinical trial to evaluate the combination of the…

GlaxoSmithKlineMerck & CoMK-3475OncologyPazopanib TabletsPharmaceuticalResearch

GlaxoSmithKline to ditch sales target-based compensation, change other global marketing practices

GlaxoSmithKline to ditch sales target-based compensation, change other global marketing practices

17-12-2013

In the wake of the bribery scandal in China, as well as a record-breaking $3 billion fine in the USA…

GlaxoSmithKlineGlobalManagementMarkets & MarketingPharmaceutical

GlaxoSmithKline to lift stake in Indian subsidiary to 75%

GlaxoSmithKline to lift stake in Indian subsidiary to 75%

16-12-2013

UK pharma major GlaxoSmithKline said this morning that it plans to increase its stake in its publicly-listed…

Asia-PacificGlaxoSmithKlineIndiaMergers & AcquisitionsPharmaceutical

Citing “unreasonable price,” New Zealand declines eculizumab funding

Citing “unreasonable price,” New Zealand declines eculizumab funding

13-12-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC has declined the funding application for eculizumab…

Alexion PharmaceuticalsAsia-PacificeculizumabGlaxoSmithKlineHematologyNew ZealandPharmaceuticalPricingRare diseasesRevoladeSoliris

New agreement with GSK provides new medicines, saves millions for New Zealand

New agreement with GSK provides new medicines, saves millions for New Zealand

11-12-2013

A new agreement with the local subsidiary of UK pharma giant GlaxoSmithKline by New Zealand’s Pharmaceutical…

Anti-viralsAsia-PacificGlaxoSmithKlineHealthcareHematologyNew ZealandPharmaceuticalPricingRespiratory and PulmonarySeretideSerevent Diskus

76 to 100 of 415 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top